Tirzepatide (Mounjaro for T2DM and Zepbound for obesity) is a novel dual agonist that targets both the GLP‐1 and GIP receptors, offering enhanced effects on glucose control and weight loss [19]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.